ACA
ANIP icon

Apis Capital Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Apis Capital Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-196,000
Closed -$15.5M – 53
2025
Q4 		$15.5M Buy
196,000
+32,000
+20% +$2.77M 2.7% 14
2025
Q3 		$15M Buy
164,000
+36,000
+28% +$2.94M 3.32% 14
2025
Q2 		$8.35M Buy
128,000
+63,000
+97% +$4.1M 2.97% 13
2025
Q1 		$4.35M Buy
+65,000
New +$3.88M 2.1% 15

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Apis Capital Advisors's ANIP Position: Q1 2026 in Review

Apis Capital Advisors sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 196,000 shares — an estimated $15.5M sold.

Apis Capital Advisors first reported a position in ANIP in Q1 2025 and held it in 4 quarters. The position peaked at $15.5M in Q4 2025. 281 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Apis Capital Advisors reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Apis Capital Advisors sold 196,000 ANI Pharmaceuticals shares in Q1 2026, an estimated $15.5M.
  • Apis Capital Advisors first reported a position in ANI Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Apis Capital Advisors's ANI Pharmaceuticals position peaked at $15.5M in Q4 2025.
  • 281 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Apis Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.